Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of IVX-A12 in Adults Participants

NCT06481579
Conditions
Healthy Participants
Interventions
IVX-A12, Licensed RSV Vaccine
Biological
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years and older
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
5
States / cities
Anaheim, California • Rolling Hills Estates, California • Hollywood, Florida + 2 more
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more
Conditions
RSV Respiratory Syncytial Virus
Interventions
AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 3 more
Conditions
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
1,530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
60 Years and older
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
11
States / cities
Denver, Colorado • Hialeah, Florida • Savannah, Georgia + 8 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT vaccine, dTpa vaccine
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Beaumont, Texas
Conditions
Respiratory Syncytial Viruses
Interventions
ABRYSVO Vaccination
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Months to 6 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Systems Biological Analysis of Immune Responses to RSV Vaccine

NCT07185399
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Moderna RSV vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
60 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

NCT06077149
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV vaccine
Biological
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, New York
Conditions
Healthy Participants
Interventions
Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
1,142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
37
States / cities
Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more